Sign In
Buy PCRX
$26.41
-0.560 (-2.08%)
At Close: Jul 31, 2026
Findings presented at ISPOR 2026 showed lower opioid consumption, reduced healthcare costs, and fewer opioid-related adverse events associated with EXPAREL use BRISBANE, Calif., May 27, 2026 (GLOBE NE
Pacira BioSciences Sets the Record Straight Regarding DOMA's Misleading Statements About Pacira's Intellectual Property Strategy
08:00am, Tuesday, 26'th May 2026
Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (
PharmaCorp Announces Definitive Agreement to Acquire PharmaChoice Canada Bannered Pharmacy in Ontario
09:27am, Monday, 25'th May 2026
Purchase price of approximately $8.2 million The acquisition represents a continued expansion of PharmaCorp's footprint in Ontario SASKATOON, Saskatchewan, May 25, 2026 (GLOBE NEWSWIRE) -- PHARMACORP
A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC
01:53pm, Thursday, 21'st May 2026
FRANK LEE AND THE BOARD HAVE OVERSEEN GROSS AND PERSISTENT UNDERPERFORMANCE FOR YEARS. WHY WOULD SHAREHOLDERS VOTE TO CONTINUE THIS UNRELENTING LACK OF TOTAL RETURN TO SHAREHOLDERS ("TRS"), WHILE ALLO
DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences
12:28pm, Wednesday, 20'th May 2026
Independent Directors, Christopher Dennis, MD, MBA, FAPA and Oliver Benton "Ben" Curtis III Outline How Their Skills and Experience Will Drive Positive Change Intend to Work Collaboratively with Incum
Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today
Pacira BioSciences: Exparel Still Supports My Original Bull Case
08:00am, Tuesday, 19'th May 2026
PCRX remains a commercial non-opioid pain company built around Exparel, Zilretta, and Iovera. That's why I think the most important catalysts for this stock, for better or worse, will be its upcoming
DOMA Perpetual Issues and Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement and WHITE Proxy Card - Urg
DOMA Perpetual Believes the Board and Management are Committing Gross Negligence by Misleading Investors About the True Risks the Business Faces; DOMA Contends This Conduct Constitutes a Failure of th
Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences
08:00am, Wednesday, 13'th May 2026
BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the live
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
04:01pm, Tuesday, 12'th May 2026
Highlights Nominees' Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLU
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 08'th May 2026
BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patie
Pacira BioSciences Mails Letter to Stockholders
04:20pm, Tuesday, 05'th May 2026
Details Success of Pacira's 5x30 Strategy and Solid First Quarter 2026 Results Reiterates Board's Unanimous Recommendation that Stockholders Vote “FOR” the Election of Pacira's Highly Qualified
PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada
05:00pm, Friday, 01'st May 2026
SASKATOON, Saskatchewan, May 01, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX), a Canadian pharmacy acquisition and ownership platform for pharma
Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
02:26pm, Friday, 01'st May 2026
PCRX Q1 earnings miss estimates as rising costs weigh on profit, but revenues top expectations on Exparel demand and growth from Zilretta and iovera.
